MGI Tech and Invitrotek Drive Genomics Progress in Türkiye at the 2nd IVT-MGI Conference
11/12/25
Offline
Istanbul, Türkiye
Share
Istanbul, Türkiye, 12 November 2025 – MGI Tech Co., Ltd. (“MGI”), a company dedicated to developing core tools and technologies that drive innovation in life sciences, successfully co-hosted the 2nd IVT-MGI Conference with its Turkish collaborator, Invitrotek A.Ş., on October 31, 2025, in Istanbul.
This flagship event brought together local and international scientists, clinicians, and industry experts to explore cutting-edge advancements in genomics, with a focus on MGI’s latest high-throughput DNBSEQ-T7+ sequencer, flexible DNBSEQ-T1+ sequencer, and STOmics spatial omics solutions—all tailored to address Türkiye’s evolving needs in research and clinical practice.
Haluk Ucdere, General Manager of Invitrotek, stated, “We are delighted to host the second IVT-MGI Conference, which is not only a meeting where MGI and our manufacturing partners share their new products and technologies, but also includes scientific lectures from Turkish and foreign speakers—and is on its way to becoming a tradition.”
Chen Fang, General Manager of MGI Europe and Africa, highlighted, “Türkiye is a key hub for MGI’s Europe and Africa expansion. Our collaboration with Invitrotek ensures that technologies like the DNBSEQ-T1+ and DNBSEQ-T7+ are not just introduced, but integrated into local workflows.
“The DNBSEQ-T1+’s CE IVDR certification in May 2025 makes it a trusted first choice for clinical labs across Türkiye, while the upcoming launch of the DNBSEQ-T7+ in early 2026 will further empower large-scale research initiatives. STOmics, in particular, opens new frontiers for Turkish scientists studying complex diseases.”
Following a morning of opening remarks and MGI’s technology portfolio highlights—including the DNBSEQ-T7+, clinically validated DNBSEQ-T1+, and STOmics spatial omics solutions—the agenda shifted to focused sessions led by a line-up of industry and academic partners, with a strong emphasis on clinical potential.
MGI kicked off this segment with insights into “Generative Lab Intelligence (GLI) and OMICS,” while Nanodigmbio shared expertise on ultra-sensitive targeted next-generation sequencing (tNGS) and oncology innovations for early screening and minimal residual disease (MRD) detection.
The afternoon sessions continued to explore real-world applications of genomics, with contributions from key players across the ecosystem. Twist Bioscience discussed strategies to unlock sample potential via advanced sequencing technologies; Turkish institutions Memorial Sağlık Grp. and Ege Üniversitesi offered local clinical perspectives on hereditary cancer research and copy number variation (CNV) analysis; and Mikrogen, Genomize, and Viagen rounded out the discussions with topics spanning NGS-based carrier screening, data analysis synergy with MGI platforms, and prenatal molecular screening.
By the conference’s close, attendees gained a holistic view of how the latest genomics tools can support Türkiye’s life sciences goals, while MGI and Invitrotek reaffirmed their commitment to fostering long-term collaboration to drive technology accessibility and innovation in the region.
Istanbul, Türkiye, 12 November 2025 – MGI Tech Co., Ltd. (“MGI”), a company dedicated to developing core tools and technologies that drive innovation in life sciences, successfully co-hosted the 2nd IVT-MGI Conference with its Turkish collaborator, Invitrotek A.Ş., on October 31, 2025, in Istanbul.
This flagship event brought together local and international scientists, clinicians, and industry experts to explore cutting-edge advancements in genomics, with a focus on MGI’s latest high-throughput DNBSEQ-T7+ sequencer, flexible DNBSEQ-T1+ sequencer, and STOmics spatial omics solutions—all tailored to address Türkiye’s evolving needs in research and clinical practice.
Haluk Ucdere, General Manager of Invitrotek, stated, “We are delighted to host the second IVT-MGI Conference, which is not only a meeting where MGI and our manufacturing partners share their new products and technologies, but also includes scientific lectures from Turkish and foreign speakers—and is on its way to becoming a tradition.”
Chen Fang, General Manager of MGI Europe and Africa, highlighted, “Türkiye is a key hub for MGI’s Europe and Africa expansion. Our collaboration with Invitrotek ensures that technologies like the DNBSEQ-T1+ and DNBSEQ-T7+ are not just introduced, but integrated into local workflows.
“The DNBSEQ-T1+’s CE IVDR certification in May 2025 makes it a trusted first choice for clinical labs across Türkiye, while the upcoming launch of the DNBSEQ-T7+ in early 2026 will further empower large-scale research initiatives. STOmics, in particular, opens new frontiers for Turkish scientists studying complex diseases.”
Following a morning of opening remarks and MGI’s technology portfolio highlights—including the DNBSEQ-T7+, clinically validated DNBSEQ-T1+, and STOmics spatial omics solutions—the agenda shifted to focused sessions led by a line-up of industry and academic partners, with a strong emphasis on clinical potential.
MGI kicked off this segment with insights into “Generative Lab Intelligence (GLI) and OMICS,” while Nanodigmbio shared expertise on ultra-sensitive targeted next-generation sequencing (tNGS) and oncology innovations for early screening and minimal residual disease (MRD) detection.
The afternoon sessions continued to explore real-world applications of genomics, with contributions from key players across the ecosystem. Twist Bioscience discussed strategies to unlock sample potential via advanced sequencing technologies; Turkish institutions Memorial Sağlık Grp. and Ege Üniversitesi offered local clinical perspectives on hereditary cancer research and copy number variation (CNV) analysis; and Mikrogen, Genomize, and Viagen rounded out the discussions with topics spanning NGS-based carrier screening, data analysis synergy with MGI platforms, and prenatal molecular screening.
By the conference’s close, attendees gained a holistic view of how the latest genomics tools can support Türkiye’s life sciences goals, while MGI and Invitrotek reaffirmed their commitment to fostering long-term collaboration to drive technology accessibility and innovation in the region.
Istanbul, Türkiye, 12 November 2025 – MGI Tech Co., Ltd. (“MGI”), a company dedicated to developing core tools and technologies that drive innovation in life sciences, successfully co-hosted the 2nd IVT-MGI Conference with its Turkish collaborator, Invitrotek A.Ş., on October 31, 2025, in Istanbul.
This flagship event brought together local and international scientists, clinicians, and industry experts to explore cutting-edge advancements in genomics, with a focus on MGI’s latest high-throughput DNBSEQ-T7+ sequencer, flexible DNBSEQ-T1+ sequencer, and STOmics spatial omics solutions—all tailored to address Türkiye’s evolving needs in research and clinical practice.
Haluk Ucdere, General Manager of Invitrotek, stated, “We are delighted to host the second IVT-MGI Conference, which is not only a meeting where MGI and our manufacturing partners share their new products and technologies, but also includes scientific lectures from Turkish and foreign speakers—and is on its way to becoming a tradition.”
Chen Fang, General Manager of MGI Europe and Africa, highlighted, “Türkiye is a key hub for MGI’s Europe and Africa expansion. Our collaboration with Invitrotek ensures that technologies like the DNBSEQ-T1+ and DNBSEQ-T7+ are not just introduced, but integrated into local workflows.
“The DNBSEQ-T1+’s CE IVDR certification in May 2025 makes it a trusted first choice for clinical labs across Türkiye, while the upcoming launch of the DNBSEQ-T7+ in early 2026 will further empower large-scale research initiatives. STOmics, in particular, opens new frontiers for Turkish scientists studying complex diseases.”
Following a morning of opening remarks and MGI’s technology portfolio highlights—including the DNBSEQ-T7+, clinically validated DNBSEQ-T1+, and STOmics spatial omics solutions—the agenda shifted to focused sessions led by a line-up of industry and academic partners, with a strong emphasis on clinical potential.
MGI kicked off this segment with insights into “Generative Lab Intelligence (GLI) and OMICS,” while Nanodigmbio shared expertise on ultra-sensitive targeted next-generation sequencing (tNGS) and oncology innovations for early screening and minimal residual disease (MRD) detection.
The afternoon sessions continued to explore real-world applications of genomics, with contributions from key players across the ecosystem. Twist Bioscience discussed strategies to unlock sample potential via advanced sequencing technologies; Turkish institutions Memorial Sağlık Grp. and Ege Üniversitesi offered local clinical perspectives on hereditary cancer research and copy number variation (CNV) analysis; and Mikrogen, Genomize, and Viagen rounded out the discussions with topics spanning NGS-based carrier screening, data analysis synergy with MGI platforms, and prenatal molecular screening.
By the conference’s close, attendees gained a holistic view of how the latest genomics tools can support Türkiye’s life sciences goals, while MGI and Invitrotek reaffirmed their commitment to fostering long-term collaboration to drive technology accessibility and innovation in the region.
Istanbul, Türkiye, 12 November 2025 – MGI Tech Co., Ltd. (“MGI”), a company dedicated to developing core tools and technologies that drive innovation in life sciences, successfully co-hosted the 2nd IVT-MGI Conference with its Turkish collaborator, Invitrotek A.Ş., on October 31, 2025, in Istanbul.
This flagship event brought together local and international scientists, clinicians, and industry experts to explore cutting-edge advancements in genomics, with a focus on MGI’s latest high-throughput DNBSEQ-T7+ sequencer, flexible DNBSEQ-T1+ sequencer, and STOmics spatial omics solutions—all tailored to address Türkiye’s evolving needs in research and clinical practice.
Haluk Ucdere, General Manager of Invitrotek, stated, “We are delighted to host the second IVT-MGI Conference, which is not only a meeting where MGI and our manufacturing partners share their new products and technologies, but also includes scientific lectures from Turkish and foreign speakers—and is on its way to becoming a tradition.”
Chen Fang, General Manager of MGI Europe and Africa, highlighted, “Türkiye is a key hub for MGI’s Europe and Africa expansion. Our collaboration with Invitrotek ensures that technologies like the DNBSEQ-T1+ and DNBSEQ-T7+ are not just introduced, but integrated into local workflows.
“The DNBSEQ-T1+’s CE IVDR certification in May 2025 makes it a trusted first choice for clinical labs across Türkiye, while the upcoming launch of the DNBSEQ-T7+ in early 2026 will further empower large-scale research initiatives. STOmics, in particular, opens new frontiers for Turkish scientists studying complex diseases.”
Following a morning of opening remarks and MGI’s technology portfolio highlights—including the DNBSEQ-T7+, clinically validated DNBSEQ-T1+, and STOmics spatial omics solutions—the agenda shifted to focused sessions led by a line-up of industry and academic partners, with a strong emphasis on clinical potential.
MGI kicked off this segment with insights into “Generative Lab Intelligence (GLI) and OMICS,” while Nanodigmbio shared expertise on ultra-sensitive targeted next-generation sequencing (tNGS) and oncology innovations for early screening and minimal residual disease (MRD) detection.
The afternoon sessions continued to explore real-world applications of genomics, with contributions from key players across the ecosystem. Twist Bioscience discussed strategies to unlock sample potential via advanced sequencing technologies; Turkish institutions Memorial Sağlık Grp. and Ege Üniversitesi offered local clinical perspectives on hereditary cancer research and copy number variation (CNV) analysis; and Mikrogen, Genomize, and Viagen rounded out the discussions with topics spanning NGS-based carrier screening, data analysis synergy with MGI platforms, and prenatal molecular screening.
By the conference’s close, attendees gained a holistic view of how the latest genomics tools can support Türkiye’s life sciences goals, while MGI and Invitrotek reaffirmed their commitment to fostering long-term collaboration to drive technology accessibility and innovation in the region.
Share this article :
Share
Sep 8, 2025
MGI Advances Genomics Collaboration at the African BioGenome Project (AfricaBP)
For the third consecutive year, MGI proudly participated in the African BioGenome Project (AfricaBP) Southern African Workshop - a flagship initiative aimed at empowering African researchers and institutions to drive genomics innovation for biodiversity, agriculture, and sustainable development.
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).